T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Status
- RECRUITING
- Phase
- PHASE2
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
- Status
- TERMINATED
- Phase
- PHASE2
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
- Status
- TERMINATED
- Phase
- PHASE1